-+ 0.00%
-+ 0.00%
-+ 0.00%

NervGen Pharma Voluntarily Delisting From TSX Venture Exchange, Effective March 16

Benzinga·03/12/2026 20:28:17
Listen to the news

NervGen Pharma Corp. ("NervGen" or the "Company") (TSXV: NGEN) (NASDAQ: NGEN), a clinical-stage biopharmaceutical company developing first-in-class neuroreparative therapeutics for spinal cord injury (SCI) and other neurotraumatic and neurologic conditions, today announced that the Company has elected to voluntarily delist its common shares from TSX Venture Exchange ("TSXV"), effective at the close of markets on March 16, 2026.